FBRX Company Profile and Key Details

Forte Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.23. This means the shares are trading above this model’s fair value.

Short-term trend indicators are bearishly aligned (SMA20 -2.54%, SMA50 1.05%, SMA200 75.26%). The stock’s 14-day RSI is 49.41 (neutral), while the ATR of 2.8 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.86% below its high and over 497.14% above its low.

The stock is currently trading near its 52-week high $10.11 and $77.20. With a market capitalization of about $1.58 billion, Forte Biosciences, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.65). Key stats such as the average daily volume over the past year has been around 1.36 million shares, volume is running light vs its 52-week average. Headquartered in Dallas, TX, Forte Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Paul A. Wagner, the company employs approximately 23 people and listed since April 13, 2017. Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase.

Forte Biosciences, Inc. generated EPS of -$4.44 over the past year. Five-year average earnings growth is 24.08%. Wall Street analysts project EPS growth of 29.76% annually over the next five years. The latest quarter delivered EPS of -$0.97. The next quarter is forecast at -$1.18. Next year's EPS is expected at -$8.62. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 1 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $77.00 to $61.00. The high target offers 0.01% upside. The low target suggests -20.77% downside. The mean target is $69.25. This offers -10.05% upside. Forte Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended August 12, 2026, missed forecasts by 10.42%. The prior quarter beat by -2.51%. Over the last six quarters, Apple has recorded several small beats. These include -4.45% in November 14, 2025.

Forte Biosciences, Inc. has 21.23 million shares outstanding. The public float is 18.67 million shares, elevated short interest at 9.36% of float. This equals 1.90 million shares. The short ratio is 0.91 days. Institutional investors hold 76.24% of the float. Insiders own 2.14%. Oliveira Steven Michael holds 2.87 million shares, Wagner Paul A. has 1.82 million shares and Hasnain Faheem has 241.72 thousand shares.

Forte Biosciences, Inc. trades at a P/E ratio of -16.77, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 9.96 trading at moderately above to book value. The P/FCF stands at -21.9, also below market averages.

Forte Biosciences, Inc. (NASDAQ:FBRX) shares are up 11.51% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Forte Biosciences, Inc. trading at a premium to the broader market with a P/E of -16.77. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $52.18, suggesting -32.22% downside. Our AI forecast model points to short-term strength (4.12% over two weeks), a medium-term rise (180.18% over three months), and a longer-term gain (1.07% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Forte Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.12%, with price expected at $80.16 by September 09, 2026, within a range of $74.99 to $85.05 3-Month Outlook: Projected rise of 180.18%, reaching $215.71 by November 24, 2026, with a range of $214.82 to $220.33. 1-Year Outlook: Projected gain of 1.07%, with price at $77.81 by August 26, 2027, within a range of $72.89 to $81.94.